Last reviewed · How we verify
HAPREP®
HAPREP is a therapeutic cancer vaccine that primes the immune system to recognize and attack cancer cells expressing shared tumor-associated antigens.
HAPREP is a therapeutic cancer vaccine that primes the immune system to recognize and attack cancer cells expressing shared tumor-associated antigens. Used for Metastatic or advanced solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | HAPREP® |
|---|---|
| Also known as | 2L polyethylene glycol with ascorbic acidl PEG-Asc |
| Sponsor | National Cancer Center, Korea |
| Drug class | Therapeutic cancer vaccine |
| Target | Patient-specific tumor neoantigens |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HAPREP is a personalized neoantigen vaccine designed to stimulate CD8+ T-cell responses against patient-specific tumor mutations. It is typically used in combination with checkpoint inhibitors to enhance anti-tumor immunity by training the immune system to target cancer-specific neoantigens identified from individual patient tumors.
Approved indications
- Metastatic or advanced solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Immune-related adverse events
Key clinical trials
- Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation (PHASE3)
- Comparison Between OSS and 2L PEG/Asc for Bowel Preparation of Elderly People (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAPREP® CI brief — competitive landscape report
- HAPREP® updates RSS · CI watch RSS
- National Cancer Center, Korea portfolio CI